Thompson Siegel & Walmsley LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)
Thompson Siegel & Walmsley LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 0.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 94,001 shares of the company’s stock after purchasing an additional 728 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Johnson & Johnson were worth $12,221,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of JNJ. Armstrong Henry H Associates Inc. boosted its stake in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Armstrong Henry H Associates Inc. now owns 497,392 shares of the company’s stock valued at $65,800,000 after buying an additional 4,306 shares during the period. Steinberg Global Asset Management boosted its stake in shares of Johnson & Johnson by 4.7% during the 2nd quarter. Steinberg Global Asset Management now owns 25,214 shares of the company’s stock valued at $3,336,000 after buying an additional 1,123 shares during the period. Bristlecone Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.0% during the 2nd quarter. Bristlecone Advisors LLC now owns 27,275 shares of the company’s stock valued at $3,608,000 after buying an additional 257 shares during the period. First Heartland Consultants Inc. boosted its stake in shares of Johnson & Johnson by 27.6% during the 2nd quarter. First Heartland Consultants Inc. now owns 20,488 shares of the company’s stock valued at $2,710,000 after buying an additional 4,428 shares during the period. Finally, Park Avenue Securities LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $1,221,000. 67.35% of the stock is owned by hedge funds and other institutional investors.
In related news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 EPS. analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were issued a $0.84 dividend. The ex-dividend date of this dividend was Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.88%.
A number of equities research analysts have issued reports on JNJ shares. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. BMO Capital Markets raised their price target on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target on the stock in a report on Wednesday, December 20th. JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $146.26.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Marea Informative and is the sole property of of Marea Informative. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.mareainformativa.com/2018/03/16/johnson-johnson-jnj-shares-bought-by-thompson-siegel-walmsley-llc-updated-updated-updated.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.